159 related articles for article (PubMed ID: 35430972)
1. An Overview of Treatment Guidelines and Methods of Synthesis of Drugs Used in Leprosy Chemotherapy.
Pinheiro LCS; Borges JC; Campos VR; Dantas LC
Mini Rev Med Chem; 2023; 23(4):497-512. PubMed ID: 35430972
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of anti-bacterial activity of Rifapentine, Clarithromycin, Minocycline, Moxifloxacin, Ofloxacin and their combinations in Murine Model of Rifampicin Resistant Leprosy.
Joseph P; Ponnaiya J; Das M; Chaitanya VS; Arumugam S; Ebenezer M
Indian J Lepr; 2016; 88(3):147-58. PubMed ID: 30207440
[TBL] [Abstract][Full Text] [Related]
3. Molecular detection of multidrug-resistant Mycobacterium leprae from Indian leprosy patients.
Lavania M; Singh I; Turankar RP; Ahuja M; Pathak V; Sengupta U; Das L; Kumar A; Darlong J; Nathan R; Maseey A
J Glob Antimicrob Resist; 2018 Mar; 12():214-219. PubMed ID: 29097343
[TBL] [Abstract][Full Text] [Related]
4. Interaction of constituents of MDT regimen for leprosy with Mycobacterium leprae HSP18: impact on its structure and function.
Chakraborty A; Ghosh R; Biswas A
FEBS J; 2022 Feb; 289(3):832-853. PubMed ID: 34555271
[TBL] [Abstract][Full Text] [Related]
5. Newer drugs in leprosy.
Grosset JH
Int J Lepr Other Mycobact Dis; 2001 Jun; 69(2 Suppl):S14-8. PubMed ID: 11757174
[TBL] [Abstract][Full Text] [Related]
6. High frequency of ofloxacin resistance patterns of Mycobacterium leprae from India: An indication to revisit second line anti-leprosy treatment regimen.
Chhabra S; Narang T; Sahu S; Sharma K; Shilpa S; Sharma A; Jain S; Singh I; Yadav R; Kaur M; Sharma R; Nadeem M; Pandey P; Minz RW; Dogra S
J Glob Antimicrob Resist; 2023 Dec; 35():262-267. PubMed ID: 37852372
[TBL] [Abstract][Full Text] [Related]
7. A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin.
Matsuoka M; Kashiwabara Y; Namisato M
Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):452-5. PubMed ID: 11332288
[TBL] [Abstract][Full Text] [Related]
8. Drug resistant-Mycobacterium leprae--results of mouse footpad studies from a laboratory in south India.
Ebenezer GJ; Norman G; Joseph GA; Daniel S; Job CK
Indian J Lepr; 2002; 74(4):301-12. PubMed ID: 12624978
[TBL] [Abstract][Full Text] [Related]
9. [New WHO recommendations for the treatment of leprosy].
Acta Leprol; 1997; 10(4):189. PubMed ID: 9527754
[No Abstract] [Full Text] [Related]
10. Evidence for
Mahajan NP; Lavania M; Singh I; Nashi S; Preethish-Kumar V; Vengalil S; Polavarapu K; Pradeep-Chandra-Reddy C; Keerthipriya M; Mahadevan A; Yasha TC; Nandeesh BN; Gnanakumar K; Parry GJ; Sengupta U; Nalini A
Am J Trop Med Hyg; 2020 Mar; 102(3):547-552. PubMed ID: 31933458
[TBL] [Abstract][Full Text] [Related]
11. Is drug-resistant Mycobacterium leprae a real cause for concern?: First approach to molecular monitoring of multibacillary Colombian patients with and without previous leprosy treatment.
Guerrero MI; Colorado CL; Torres JF; León CI
Biomedica; 2014 Apr; 34 Suppl 1():137-47. PubMed ID: 24968045
[TBL] [Abstract][Full Text] [Related]
12. Clinical pilot study: Clarithromycin efficacy in multibacillary leprosy therapy.
Gunawan H; Sasmojo M; Putri HE; Avriyanti E; Hindritiani R; Suwarsa O
Int J Mycobacteriol; 2018; 7(2):152-155. PubMed ID: 29900892
[TBL] [Abstract][Full Text] [Related]
13. Ofloxacin-Containing Multidrug Therapy in Ambulatory Leprosy Patients: A Case Series.
Faust L; Klowak M; MacRae C; Kopalakrishnan S; Showler AJ; Boggild AK
J Cutan Med Surg; 2021; 25(1):45-52. PubMed ID: 32869655
[TBL] [Abstract][Full Text] [Related]
14. Metabolism and interactions of antileprosy drugs.
George J
Biochem Pharmacol; 2020 Jul; 177():113993. PubMed ID: 32339493
[TBL] [Abstract][Full Text] [Related]
15. Repurposing Drugs to Combat Drug Resistance in Leprosy: A Review of Opportunities.
Sharma M; Singh P
Comb Chem High Throughput Screen; 2022; 25(10):1578-1586. PubMed ID: 34620073
[TBL] [Abstract][Full Text] [Related]
16. Ofloxacin resistance in multibacillary new leprosy cases from Purulia, West Bengal: a threat to effective secondary line treatment for rifampicin-resistant leprosy cases.
Ahuja M; Singh I; Lavania M; Pathak VK; Darlong J; Turankar RP; Hembrom S; Singh SV; Sengupta U
J Glob Antimicrob Resist; 2022 Sep; 30():282-285. PubMed ID: 35717020
[TBL] [Abstract][Full Text] [Related]
17. The frequency of drug resistance mutations in Mycobacterium leprae isolates in untreated and relapsed leprosy patients from Myanmar, Indonesia and the Philippines.
Matsuoka M; Budiawan T; Aye KS; Kyaw K; Tan EV; Cruz ED; Gelber R; Saunderson P; Balagon V; Pannikar V
Lepr Rev; 2007 Dec; 78(4):343-52. PubMed ID: 18309708
[TBL] [Abstract][Full Text] [Related]
18. Dapsone drug resistance in the MDT era.
Roche PW; Neupane KD; Failbus SS; Butlin CR
Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):323-5. PubMed ID: 11221097
[No Abstract] [Full Text] [Related]
19. Drug resistance patterns in Mycobacterium leprae isolates from relapsed leprosy patients attending The Leprosy Mission (TLM) Hospitals in India.
Lavania M; Jadhav RS; Chaitanya VS; Turankar R; Selvasekhar A; Das L; Darlong F; Hambroom UK; Kumar S; Sengupta U
Lepr Rev; 2014 Sep; 85(3):177-85. PubMed ID: 25509718
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy of lepromatous leprosy: recent developments and prospects for the future.
Gelber RH
Eur J Clin Microbiol Infect Dis; 1994 Nov; 13(11):942-52. PubMed ID: 7698121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
